薬理と治療

Abstract

Objective　We discuss the efficacy of nattokinase in subjects who have hypertension; the high normal blood pressure in this paper. The data reported here are based on a re-analysis of a previously published study on this trial,26） where we have excluded people with Stage 2 hypertension from our analysis. Our goal was to document that the overall effects of Nattokinase consumption reported by Jensen, et al was also statistically significant in the subgroup with high-normal blood pressure. Methods　This paper presents a sub-group analysis of a previously published study, specifically to document the significant reduction in blood pressure, excluding people from the original study who had Stage 2 hypertension. The study adopted in to assess the efficacy of nattokinae（NSK-SD）is a randomized, double-blind, placebo-controlled, parallel-group clinical study. 79 subjects joined screening for high blood pressure（high-normal blood pressure or high-gradeⅠ hypertension）referring to the study done in Asia. They took placebo or 110 mg nattokinase per day for the 8week study duration. Result　67 subjects were chosen out of 79 subjects in result of screening. Diastolic blood pressure at 8th week in nattokinase group was significantly lower than placebo group（P＜0.05）. The degree of reduction of diastolic blood pressure in male was significantly different compared with placebo group（P＜0.05）. No significant difference was found in diastolic blood pressure in women. In Stratified analyses, we found no significant difference in systolic blood pressure in hypertension subject. However, compared with placebo group, significant differences in diastolic blood pressure were found（P＜0.05）. Conclusion　In hypertension subject, nattokinse leads to beneficial changes in blood pressure.